XILAM
14.5.2018 19:00:11 CEST | Business Wire | Press release
Regulatory News:
The growth of the audience (number of views) garnered by Xilam’s (Paris:XIL) programmes on YouTube has been accelerating over recent months.
While the number of views rose 21% in 2017, Xilam has seen an impressive 79% increase in the number of views between November 2017 and April 2018, in comparison to the same period last year. Based on this trend, Xilam’s programmes, which were viewed 2.6 billion times on YouTube in 2017, are expected to garner close to 4 billion views in 2018 .
Even more remarkably, revenues over this same six-month period increased 126%. This differential can be explained by a substantial improvement in the monetisation factors.
In addition to the viewing figures, the number of subscribers is also increasing quickly across Xilam’s channels, rising 50% over the same six-month period. Xilam is anticipating reaching close to 5 million total subscribers by the end of 2018 (in comparison to 2.2 million in December 2017). The official Zig and Sharko channel will, by then have reached the same number of subscribers as Oggy & the Cockroaches .
This progress is due to a number of factors:
- The remarkable work by Xilam’s digital team in managing Xilam’s YouTube channels, creating new channels as well as increasing the volume of content being posted (x3 in comparison to the previous year). The teams have also developed a significant expertise in SEO (Search Engine Optimization).
- In a number of developed western markets, including the US, the most successful Xilam programmes are included in Google Preferred, the program that aggregates YouTube's top content into easy-to-buy packages for brand advertisers.
- While revenues made solid gains in Asia-Pacific, they rose even more quickly in North America. This is the result of the recent release of new seasons of Oggy & the Cockroaches and Zig and Sharko on Netflix and Amazon. This massive exposure boost has had a spectacular impact on revenues from YouTube, in particular on the official Zig and Sharko channel which now generates 45% of its revenues in the United States.
Xilam proves to be at the very heart of the digital transformation and the globalisation it is generating. This range of linear and non-linear media is combining forces on a global scale to support Xilam’s premium programmes, and this convergence is benefiting everyone.
This trend will certainly underpin growth in Xilam’s Catalogue revenue.
Marc du Pontavice, Chairman and CEO of Xilam, said: “I am delighted with both the amazing work carried out by Xilam’s teams, and the essential support and guidance provided by our partners at YouTube and YouTube Kids. These platforms enhance the accessibility of Xilam’s programmes worldwide, offering children the chance to have high-quality entertainment at their fingertips .”
Gregory Dray, Director, Head of Kids/Family and Learning, EMEA, Google/YouTube added: “Xilam's universally loved programs have naturally found a unique place on global platforms like YouTube and YouTube Kids. The success of Xilam’s content is a testament to its quality and universality. We are also delighted to see Xilam's commitment to developing a specific expertise in audience development, channel management and programming strategies. As such, the company is well positioned to fully benefit from the rapid growth of YouTube Kids around the world.”
About Xilam
Xilam is one of Europe’s leading animation companies, creating, producing and distributing original children’s and family entertainment content across TV, film and digital media platforms.
Founded in 1995 by Marc du Pontavice, Xilam owns a catalogue of more than 2,000 animated episodes and three feature films including strong brands such as Oggy & the Cockroaches, Zig & Sharko, The Daltons and its first preschool series, Paprika.
Broadcast in over 190 countries on all the major TV networks and digital platforms, in particular garnering over 2.6 billion views on YouTube in 2017, Xilam’s programme catalogue makes the company one of the top global content providers in animation.
Xilam employs more than 400 people, including 300 artists, who are based across its four studios located in Paris, Lyon, Angoulême and Ho-Chi-Minh City in Vietnam.
Xilam is listed on Compartment B of Euronext Paris
PEA-eligible
SRD
long-eligible
ISIN code: FR0004034072 / Ticker: XIL
86-90, rue Notre-Dame de Nazareth – 75003 PARIS – Tel: +33 (0)1 40 18 72
00 – Fax: +33 (0)1 40 03 02 26
A société anonyme
(public
limited company) with share capital of EUR 446,500 Paris Trade and
Companies Register (RCS): 423 784 610 – SIRET: 423 784 610 00044 – APE
921 A
View source version on businesswire.com: https://www.businesswire.com/news/home/20180514006096/en/
Contact:
Contacts at Xilam
Marc du Pontavice, +33 1 40 18 72 00
Chairman
and CEO
or
Contacts Google/YouTube
Google/YouTube
– Press Service
presse-fr@google.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
